Explanatory Note: This 13D relates to shares of Common Stock, $0.0001 par value per share (“Common Stock”), of Black Diamond Therapeutics, Inc., a Delaware corporation (the “Issuer”).
Item 1. Security and Issuer
The class of equity security to which this statement on Schedule 13D relates is the Common Stock of the Issuer. The address of the principal executive offices of the Issuer is 139 Main Street, Cambridge, MA 02142. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 2. Identity and Background
(a) This Schedule 13D is filed by Versant Venture Capital VI, L.P. (“Versant VI”), Versant Voyageurs I Parallel, L.P. (“Versant I Parallel”), Versant Voyageurs I, L.P. (“Versant Voyageurs I”), Versant Vantage I, L.P. (“Versant Vantage I”), Versant Ventures VI GP, L.P. (“Versant Ventures VI GP”), Versant Ventures VIGP-GP, LLC (“Versant Ventures VIGP-GP”), Versant Voyageurs I GP, L.P. (“Versant Voyageurs I GP LP”), Versant Voyageurs I GP Company (“Versant Voyageurs I GP”), Versant Vantage I GP, L.P. (“Versant Vantage I GP LP”) and Versant Vantage IGP-GP, LLC (“Versant Vantage I GP-GP” and, with Versant VI, Versant I Parallel, Versant Voyageurs I, Versant Vantage I, Versant Ventures VI GP, Versant Ventures VIGP-GP, Versant Voyageurs I GP LP, , Versant Voyageurs I GP, and Versant Vantage I GP LP, collectively, the “Reporting Persons”). Versant Ventures VIGP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Versant Ventures VIGP-GP and Versant Ventures VI GP share voting and dispositive power over the shares held by Versant VI. Versant Ventures VIGP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant Voyageurs I GP LP. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Voyageurs I GP LP, Versant Ventures VI GP and Versant Ventures VIGP-GP share voting and dispositive power over the shares held by Versant I Parallel. Versant Voyageurs I GP is the general partner of Versant Voyageurs I and shares voting and dispositive power over the shares held by Versant Voyageurs I. Versant Vantage I GP LP is the general partner of Versant Vantage I, and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Versant Vantage I GP LP and Versant Vantage I GP-GP share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.
(b) The principal business and principal business office of the Reporting Persons is Versant Ventures, One Sansome Street, Suite 3630, San Francisco, CA 94104.
(c) The principal business of the Reporting Persons is venture capital investments.
(d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial of administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) Each of the Reporting Persons is incorporated in the state of Delaware.
Item 3. Source and Amount of Funds or Other Consideration
Prior to the Issuer’s initial public offering (the “IPO”), the Reporting Persons purchased an aggregate of 1,000,000 shares of Common Stock, 20,000,000 shares of Series A Preferred Stock, 3,941,142 shares of Series B Preferred Stock and 5,186,048 shares of Series C Preferred Stock for an aggregate purchase price of $57,798,813 in a series of private placement transactions. Upon the closing of the IPO, all shares of Series A, Series B and Series C Preferred Stock held by the Reporting Persons automatically converted into shares of Common Stock of the Issuer on a1-for-3.01581 basis.
12